Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Padcev (enfortumab vedotin) for the Treatment of Urothelial Cancer

Drug Name

Padcev™ (enfortumab vedotin)

Developers

Astellas Pharma and Seattle Genetics

Therapy Class

Antibody-drug conjugate

Product Description

Nectin-4-directed antibody-drug conjugate

Current Indication

Advanced urothelial cancer

Market Sector

Oncology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top